EKTA.B

47.88

-2.52%↓

EKTA.B

47.88

-2.52%↓

EKTA.B

47.88

-2.52%↓

EKTA.B

47.88

-2.52%↓

EKTA.B

47.88

-2.52%↓

Search

Vivesto AB

Geschlossen

0.22

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.22

Max

0.22

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.4M

-8.3M

EPS

-0.015

Angestellte

4

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.1M

123M

Vorheriger Eröffnungskurs

0.22

Vorheriger Schlusskurs

0.22

Vivesto AB Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Juli 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FCC Approves U.S. Cellular Sale to T-Mobile

11. Juli 2025, 17:28 UTC

Wichtige Markttreiber

SharpLink Gaming Gains on Ethereum Purchase

11. Juli 2025, 16:57 UTC

Ergebnisse

BASF Cuts Outlook on Global Economy Uncertainty

12. Juli 2025, 17:01 UTC

Ergebnisse

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12. Juli 2025, 14:53 UTC

Ergebnisse

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12. Juli 2025, 02:24 UTC

Akquisitionen, Fusionen, Übernahmen

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12. Juli 2025, 02:05 UTC

Akquisitionen, Fusionen, Übernahmen

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12. Juli 2025, 02:05 UTC

Akquisitionen, Fusionen, Übernahmen

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12. Juli 2025, 02:05 UTC

Akquisitionen, Fusionen, Übernahmen

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11. Juli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. Juli 2025, 19:46 UTC

Akquisitionen, Fusionen, Übernahmen

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. Juli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. Juli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. Juli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. Juli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. Juli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. Juli 2025, 16:42 UTC

Ergebnisse

BASF Cuts Outlook on Global Economic Uncertainty

11. Juli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. Juli 2025, 16:05 UTC

Ergebnisse

BASF Will Publish Half-Year Results on July 30

11. Juli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. Juli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. Juli 2025, 16:03 UTC

Ergebnisse

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. Juli 2025, 16:02 UTC

Ergebnisse

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. Juli 2025, 16:01 UTC

Ergebnisse

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. Juli 2025, 16:00 UTC

Ergebnisse

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. Juli 2025, 15:59 UTC

Ergebnisse

BASF Cuts 2025 Earnings View

11. Juli 2025, 15:58 UTC

Ergebnisse

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. Juli 2025, 15:57 UTC

Ergebnisse

BASF 2Q EBIT Before Special Items EUR810M

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Peer-Vergleich

Kursveränderung

Vivesto AB Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.